A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC
18h agoen
From the article
Conditions : NSCLC Interventions : Drug: SYS6010 Sponsors : Sichuan University Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
ClinicalKey
clinicalkey.com·1mo ago
SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial
doi.org·6d ago
Lipid nanoparticle platform delivers chemo drug and RNA to boost immune response against lung cancer
Researchers at the University of Arizona have developed a nanotechnology-based platform using lipid nanoparticles to deliver a chemotherapy
news-medical.net·13d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.